475 related articles for article (PubMed ID: 18713852)
1. Posaconazole: an oral triazole with an extended spectrum of activity.
Rachwalski EJ; Wieczorkiewicz JT; Scheetz MH
Ann Pharmacother; 2008 Oct; 42(10):1429-38. PubMed ID: 18713852
[TBL] [Abstract][Full Text] [Related]
2. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
3. Posaconazole: Use in the Prophylaxis and Treatment of Fungal Infections.
Clark NM; Grim SA; Lynch JP
Semin Respir Crit Care Med; 2015 Oct; 36(5):767-85. PubMed ID: 26398542
[TBL] [Abstract][Full Text] [Related]
4. Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update.
Smith WJ; Drew RH; Perfect JR
Expert Rev Anti Infect Ther; 2009 Mar; 7(2):165-81. PubMed ID: 19254165
[TBL] [Abstract][Full Text] [Related]
5. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.
Nagappan V; Deresinski S
Clin Infect Dis; 2007 Dec; 45(12):1610-7. PubMed ID: 18190324
[TBL] [Abstract][Full Text] [Related]
6. Posaconazole: a new oral antifungal agent with an expanded spectrum of activity.
Morris MI
Am J Health Syst Pharm; 2009 Feb; 66(3):225-36. PubMed ID: 19179636
[TBL] [Abstract][Full Text] [Related]
7. Posaconazole: a broad-spectrum triazole antifungal.
Torres HA; Hachem RY; Chemaly RF; Kontoyiannis DP; Raad II
Lancet Infect Dis; 2005 Dec; 5(12):775-85. PubMed ID: 16310149
[TBL] [Abstract][Full Text] [Related]
8. [The latest data on posaconazole].
Paugam A
Med Mal Infect; 2007 Feb; 37(2):71-6. PubMed ID: 17267154
[TBL] [Abstract][Full Text] [Related]
9. Posaconazole: a new broad-spectrum antifungal agent.
Kwon DS; Mylonakis E
Expert Opin Pharmacother; 2007 Jun; 8(8):1167-78. PubMed ID: 17516880
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients.
Winston DJ; Bartoni K; Territo MC; Schiller GJ
Biol Blood Marrow Transplant; 2011 Apr; 17(4):507-15. PubMed ID: 20460163
[TBL] [Abstract][Full Text] [Related]
11. Posaconazole: clinical pharmacology and potential for management of fungal infections.
Groll AH; Walsh TJ
Expert Rev Anti Infect Ther; 2005 Aug; 3(4):467-87. PubMed ID: 16107193
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.
Krishna G; Martinho M; Chandrasekar P; Ullmann AJ; Patino H
Pharmacotherapy; 2007 Dec; 27(12):1627-36. PubMed ID: 18041883
[TBL] [Abstract][Full Text] [Related]
13. Posaconazole: a next-generation triazole antifungal.
Farowski F; Vehreschild JJ; Cornely OA
Future Microbiol; 2007 Jun; 2(3):231-43. PubMed ID: 17661696
[TBL] [Abstract][Full Text] [Related]
14. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
[TBL] [Abstract][Full Text] [Related]
15. Posaconazole.
Keating GM
Drugs; 2005; 65(11):1553-67; discussion 1568-9. PubMed ID: 16033292
[TBL] [Abstract][Full Text] [Related]
16. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.
Raad II; Graybill JR; Bustamante AB; Cornely OA; Gaona-Flores V; Afif C; Graham DR; Greenberg RN; Hadley S; Langston A; Negroni R; Perfect JR; Pitisuttithum P; Restrepo A; Schiller G; Pedicone L; Ullmann AJ
Clin Infect Dis; 2006 Jun; 42(12):1726-34. PubMed ID: 16705579
[TBL] [Abstract][Full Text] [Related]
17. Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia.
Döring M; Eikemeier M; Cabanillas Stanchi KM; Hartmann U; Ebinger M; Schwarze CP; Schulz A; Handgretinger R; Müller I
Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1189-200. PubMed ID: 25680318
[TBL] [Abstract][Full Text] [Related]
18. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study.
Auberger J; Lass-Flörl C; Aigner M; Clausen J; Gastl G; Nachbaur D
J Antimicrob Chemother; 2012 Sep; 67(9):2268-73. PubMed ID: 22653819
[TBL] [Abstract][Full Text] [Related]
19. Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections.
Groll AH; Walsh TJ
Mycoses; 2006; 49 Suppl 1():7-16. PubMed ID: 16961576
[TBL] [Abstract][Full Text] [Related]
20. Use of posaconazole in the treatment of invasive fungal infections.
Mehta AK; Langston AA
Expert Rev Hematol; 2009 Dec; 2(6):619-30. PubMed ID: 21082953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
